Development of novel therapeutic methods for innovative bladder cancer by drug repositioning

• Project/Area Number: 15K10613
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Urology
• Research Institution: Hyogo Medical University
• Principal Investigator: GOTOH AKINOBU 兵庫医科大学, 医学部, 教授 (70283885)
• Co-Investigator(Kenkyū-buntansha): 長屋 寿雄 兵庫医科大学, 医学部, 助教 (60464343)
• Project Period (FY): 2015-04-01 – 2018-03-31
• Project Status: Completed (Fiscal Year 2017)
• Budget Amount: ¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000); Fiscal Year 2017: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000); Fiscal Year 2016: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000); Fiscal Year 2015: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
• Keywords: 膀胱癌 / ナフトピジル / ドラッグ・リポジショニング / QOL

Outline of Final Research Achievements

Bladder cancer has a high recurrence rate and low survival rate, and patient's quality of life are significantly reduced due to side effects of treatment and surgical treatment. In response, we aimed to develop novel therapeutic and preventive methods focusing on QOL using naftopidil, an α1 blocker-type oral dysuria treatment, by taking advantage of the idea of drug repositioning (DR). We were able to prepare a formulation that can expect antitumor effect from two directions by naftopidil in blood and its urinary metabolite. It is a promising achievement of establishing a novel therapeutic method for bladder cancer with safety- established naftopidil, its application for prevention of recurrence, and development of novel anticancer drugs.

Research Products

• [Journal Article] Autophagy Induced by Naftopidil Inhibits Apoptosis of Human Gastric Cancer Cells. (2018)
  • Author(s): Nakamura Azumi, Matsunaga Wataru, Gotoh Akinobu.
  • Journal Title: Anticancer Res. Volume: 38 Issue: 2 Pages: 803-809
  • DOI: 10.21873/anticanres.12287
  • Peer Reviewed
• [Journal Article] Piperazine-based alpha-1 AR blocker, naftopidil, selectively suppresses malignant human bladder cells via induction of apoptosis. (2016)
  • Author(s): Nakagawa Yusuke U, Nagaya Hisao, Miyata Takeaki, Wada Yoshitaka, Oyama Tsunehiro, Gotoh Akinobu.
  • Journal Title: Anticancer Res. Volume: 36 Pages: 1563-1570
  • Peer Reviewed / Acknowledgement Compliant
• [Journal Article] Repositioned alpha-1 adrenoceptor blockers as anti-tumor drugs. (2015)
  • Author(s): Nagaya Hisao, Nakagawa Yusuke U, Gotoh Akinobu.
  • Journal Title: Personalized Medicine Universe Volume: 4 Pages: 23-26
  • Peer Reviewed
• [Presentation] 未分化胃がん細胞においてナフトピジルはオートファジーを誘導する(Naftopidil induces autophagy in undifferentiated gastric cancer cells.) (2017)
  • Author(s): 中村安澄、松永 渉、宮田剛彰、小山倫浩、後藤章暢.
  • Organizer: 第76回日本癌学会学術総会
• [Presentation] 未分化胃がん細胞に対するナフトピジルの抗腫瘍効果(Antitumor effect of naftopidil against undifferentiated gastric cancer cells.) (2016)
  • Author(s): 中村安澄, 長屋寿雄, 宮田剛彰, 小山倫浩, 松本浩彦, 後藤章暢.
  • Organizer: 第75回日本癌学会学術総会
  • Place of Presentation: パシフィコ横浜（神奈川県横浜市）
• [Presentation] 排尿障害治療薬による抗腫瘍メカニズムの解明 (2016)
  • Author(s): 中村安澄, 長屋寿雄, 和田義孝, 小野義春, 後藤章暢.
  • Organizer: 第22回国際個別化医療学会学術集会
  • Place of Presentation: 大崎ブライトコアホール（東京都品川区）
• [Presentation] ナフトピジルの新規抗がん剤としての適応拡大に関する研究 (2015)
  • Author(s): 中村安澄, 長屋寿雄, 中川佑介, 宮田剛彰, 小山倫浩, 松本浩彦, 後藤章暢
  • Organizer: 第21回国際個別化医療学会学術集会
  • Place of Presentation: ナレッジキャピタルコングレコンベンションセンター（大阪府、大阪市）
  • Year and Date: 2015-10-17
• [Presentation] ドラッグリポジショニング法を用いた新規抗がん剤の開発(Development of the new anti-cancer drug using drug repositioning methods.) (2015)
  • Author(s): 長屋寿雄, 中川佑介, 馬渕美雪, 宮田剛彰, 小山倫浩, 松本浩彦, 後藤章暢
  • Organizer: 第74回日本癌学会学術総会
  • Place of Presentation: 名古屋国際会議場（愛知県、名古屋市）
  • Year and Date: 2015-10-09
• [Presentation] 革新的膀胱癌新規治療法の開発 (2015)
  • Author(s): 中川佑介, 長屋寿雄, He, Yun-Chi, 清水 忠, 馬渕美雪, 田中明人, 後藤章暢
  • Organizer: 第103回日本泌尿器科学会総会
  • Place of Presentation: 石川県立音楽堂、ANAクラウンプラザホテル金沢、ホテル日航金沢、金沢市アートホール他（石川県、金沢市）
  • Year and Date: 2015-04-19